



The role of AIP mutations in pituitary adenomas: 10 years on
Adrian F. Daly1 ● Albert Beckers1
Received: 25 November 2016 / Accepted: 30 November 2016
© Springer Science+Business Media New York 2016
Pituitary adenomas causing clinical symptoms occur in
about 1/1000 of the general population, making them one of
the main tumors encountered by endocrinologists [1]. In
practice, pituitary tumor etiology is rarely known, with 5%
of cases having a genetic or hereditary background [2].
These include syndromes like multiple endocrine neoplasia
(MEN) 1, familial isolated pituitary adenomas (FIPA),
MEN4, Carney complex, McCune-Albright syndrome and
X-linked acrogigantism (X-LAG), among others [3, 4].
Among the genetic causes, mutation of the aryl hydro-
carbon receptor interacting protein (AIP) gene has received
the most research interest in recent times. The publication
by Ramírez-Rentería and colleagues in the current issue of
Endocrine adds the Mexican experience to this body of
work from around the world [5]. It is now the 10th anni-
versary of the discovery of AIP as a pituitary adenoma
predisposition gene by Vierimaa et al. [6]. In that study
germline AIP mutations led generally to the familial
occurrence of acromegaly and prolactinomas. Primarily,
that study was focused on large kindreds from Finland that
had a p.Q14X AIP mutation, while other AIP mutations
were also reported, including p.R304X in Italy. This latter
mutation, present in the current Mexican cohort, has been
shown to be the most frequently reported AIP mutation
worldwide and founder mutations have been established in
Italy and Northern Ireland [7, 8].
Over the last decade more than 150 publications have
dealt with aspects of AIP function and its role in pituitary
tumorigenesis [9]. From this body of work some char-
acteristics of the role of AIP mutations in the clinical setting
have emerged. While acromegaly and prolactinomas
account for the vast majority of AIP mutation related
pituitary adenomas, rare cases of non-functioning adeno-
mas, Cushing’s disease and TSH-secreting adenomas have
been reported. In general pituitary adenomas associated
with AIP mutations are more aggressive than non-mutated
cases. They occur at a younger age and are larger at ﬁrst
symptoms and diagnosis. In the setting of acromegaly, this
is also accompanied by a reduced responsiveness to soma-
tostatin analogs, which complicates management [10].
While the mechanism behind this is still unclear, AIP
staining intensity is now acknowledged as a marker of
somatostatin analog responsiveness in acromegaly irre-
spective of AIP mutation status [11, 12]. Despite this pro-
ﬁle, it remains uncertain if somatostatin analog resistance
per se is a criterion for deﬁning a suitable population for
screening for AIP mutations.
Among FIPA kindreds about 15–20% are carriers of AIP
mutations. Patients with sporadic pituitary macroadenomas
that occur during childhood/adolescence and early adult-
hood also should be considered to be at risk for an AIP
mutation (12–20%). The young age at onset and the pro-
pensity for causing somatotropinomas means that AIP
mutations are strongly associated with pituitary gigantism
and represent the single most frequent genetic cause of
pituitary gigantism [13]. The study by Ramírez-Rentería
et al. conﬁrms that AIP mutations explain a small minority
(7%) of sporadic acromegaly patients and that these patients
exhibit aggressive features and an earlier age at onset than
non-mutated cases. They also studied DNA extracted from a
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historic case of gigantism and identiﬁed an AIP variant that
previously was reported as being non pathological. It may
be that this gigantism case is part of the >50% of cases in
which no known genetic cause has been found to date. It
also raises the question of how we call an AIP variant as
being non-pathological vs. a pathological mutation. This is
a challenge in many genetic conditions, particularly with the
routine use of next-generation sequencing and whole exome
sequencing that provide rich datasets that are heavily laden
with variants. While in silico models can help, they are
often contradictory in their conclusions and no single model
should be relied upon. There are now multiple in vitro
models of AIP function, each of which appears to target a
different pathway. While the results of these experiments
can be persuasive, they raise an important issue. Although
there is agreement that AIP mutations are associated with
aggressive pituitary adenomas, there is still no consensus on
how this occurs and whether AIP is always the primary
driver of tumorigenesis. Should AIP have a multifaceted
functionality in the pituitary (as suggested by the multiple
in vitro models), it may be that AIP mutations could drive or
facilitate tumor formation via a variety of routes. As more
information accrues, variants that are considered as clini-
cally pathological today could be reclassiﬁed as innocuous
based on integrated analyses of in silico and in vitro
models. The reverse would also be true. After the ﬁrst
decade of research on AIP in the pituitary we have a good
understanding of what AIP mutations do in the clinical
setting but we have a way to go before determining how
they do it.
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